VNRX logo

VOLITIONRX LTD

VNRXNYSE AMERICAN
🏆 #5177 by market capEarnings Nov 12US Equity
$0.18▼ $0.00 (−2.27%)
Market closed · at close
🔔
Track VNRX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.3%
7d▲ 8.3%
14d▼ 4.8%
30d▼ 28.8%
ytd▼ 96.4%
1y▼ 97.9%
🏦Market Cap
$2M
Small Cap
📈Revenue Growth (YoY)
40.0%
High Growth
📊Gross Margin
89.7%
High
💵FCF Margin
-790.3%
Thin
⚖️P/S Ratio
0.9x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.17 – $0.19
52-Week Range
$0.16 – $9.60
Volume (shares)
7,410
Avg Volume (shares)
—
Shares Outstanding
12.0M
Next Earnings
2026-11-12

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$398,657
P/E Ratio
-0.0
P/S Ratio
0.9x
EPS (TTM)
$-2.80
Dividend Yield
0.00%
Dilution (1yr)
+23.5%
VNRX logo

VOLITIONRX LTD

VNRX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2M▲ +40.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$21M▼ −21.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$20M▼ −25.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
5.3M▲ +23.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$10M▼ −$8M YoY
StockOtter · stockotter.space

About VOLITIONRX LTD

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
11 analysts
Strong Buy2
Buy7
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.